Despite meeting or beating analysts' earnings for a streak that stretches back half a decade, Abbott Labs (NYSE: ABT) hasn't been able to get much love from investors.

Quarter

Analysts' Estimated Non-GAAP EPS

Actual Non-GAAP EPS

Difference

Price Change on Day of Earnings Release

Q3 2010

$1.04

$1.05

$0.01

(0.9%)

Q2 2010

$1.00

$1.01

$0.01

2.5%

Q1 2010

$0.80

$0.84

$0.04

(2.4%)

Q4 2009

$1.17

$1.18

$0.01

(1.1%)

Q3 2009

$0.90

$0.92

$0.02

3.1%

Q2 2009

$0.89

$0.89

$0.00

(2.6%)

Q1 2009

$0.70

$0.73

$0.03

(4.6%)

Source: Earnings.com and Capital IQ, a division of Standard & Poor's.

Yesterday's downturn, which started out worse than it ended, was likely due to the top line. Sales increased 11.8% after the acquisition of Solvay Pharmaceuticals, but missed analysts' estimates considerably.

Earnings are certainly what counts, and the cost cutting moves that allowed Abbott to beat estimates are commendable. But you can't cut costs forever, and revenue can often give hints about what is going to happen in the future.

Abbott's nutritional business fell 1.5% because of last month's recall of Similac baby formula. The plant that had the beetle infestation is back in production, but it's not clear how much the bad press could have pushed parents to formulas made by Mead Johnson Nutrition (NYSE: MJN) and Nestle.

And there's the loss of obesity drug Meridia, which wasn't a make or break product, but it's always better to have revenue than not.

Sales of anti-inflammatory Humira shot up 12.6%, competing well against Johnson & Johnson (NYSE: JNJ) and Merck's (NYSE: MRK) Remicade and Abbott Labs (NYSE: ABT) and Pfizer's (NYSE: PFE) Enbrel. But stellar growth is always a double-edged sword; the top-selling drug helps grow revenue, but the increase just makes Abbott more dependent on the drug, which made up nearly a fifth of Abbott's sales in the third quarter.

Abbott is guiding for full-year non-GAAP earnings between $4.16 and $4.18 per share, which would be about 12% growth over last year. Trading at about 12.7 times this year's guidance, maybe investors have already priced most of that earnings beat in.

Interested in keeping track of Abbott? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Abbott.

Pfizer is a Motley Fool Inside Value pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor pick. The Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.